ORIC Pharmaceuticals: Updates Did Not Bode Well For This Valuation
Source: SeekingAlpha
2026-04-01 13:14:49 ET
Topline Summary and Update
My outlook on ORIC Pharmaceuticals, Inc. ( ORIC ) to date has been one of substantial caution, with my latest article continuing to affirm a Hold sentiment given how aggressively the market was pricing the stock on the basis of early trial data. While there were signals that their targeted therapy could ascend to "best in class" therapy status in prostate cancer, I had too many concerns to make it to a Buy sentiment....
Read the full article on Seeking Alpha
For further details see:
ORIC Pharmaceuticals: Updates Did Not Bode Well For This Valuation
Oric Pharmaceuticals Inc.
NASDAQ: ORIC
ORIC Trading
-28.47% G/L:
$9.07 Last:
7,586,494 Volume:
$10.25 Open:
ORIC Latest News
April 01, 2026 09:48:43 am
Oric Pharmaceuticals (NASDAQ:ORIC) Given New $17.00 Price Target at Wedbush
March 31, 2026 04:05:00 pm
ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile
ORIC Stock Data
$1,023,561,322
83,384,701
0.22%
39
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
